[ad_1]
Biohaven CEO Vlad Coric informed CNBC Tuesday a latest approval of the corporate’s migraine drug will “change the paradigm” of migraine prevention and remedy.
The U.S. Meals and Drug Administration final week permitted the medication, Nurtec ODT, for preventative remedy of migraines. That comes a couple of 12 months after Nurtec was first launched to deal with the signs of debilitating complications, making it the primary capsule permitted for each acute remedy and prevention, in line with Coric.
“This can be a monumental approval for Biohaven and sufferers with migraine,” Coric mentioned in a “Mad Cash” interview with Jim Cramer.
“I have been working towards medication for 25 years, and that is the primary time we’ve a single migraine medicine that may do each of these items,” Coric mentioned. “That is going to vary the paradigm by which migraine is handled.”
The New Haven, Connecticut-based pharmaceutical firm has recruited movie star names like actress Whoopi Goldberg and mannequin Khloe Kardashian to advertise the remedy.
Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from the place it final traded earlier than the announcement.
[ad_2]
Source link